Drug & intervention

cyclophosphamide

RxCUI 3002

Clinical trials596
Recruiting56
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Cyclophosphamide

Cyclophosphamide (CP), also known as cytophosphane among other names, is a medication used as chemotherapy and to suppress the immune system. As chemotherapy it is used to treat lymphoma, multiple myeloma, leukemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma. As an immune suppressor it is used in nephrotic syndrome, ANCA-associated vasculitis, and following organ transplant, among other conditions. It is taken by mouth or injection into a vein. Most people develop side effects. Common side effects include low white blood cell counts, loss of appetite, vomiting, hair loss, and bleeding from the bladder. Other severe side effects include an increased future risk of cancer, infertility, allergic reactions, and pulmonary fibrosis. Cyclophosphamide is in the alkylating agent and nitrogen mustard family of medications. It is believed to work by interfering with the duplication of DNA and the creation of RNA. Cyclophosphamide was approved for medical use in the United States in 1959. It is on the World Health Organization's List of Essential Medicines.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory DiseaseNCT07509034 · 2026-10-12
RECRUITING
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid TumoursNCT07297667 · 2026-08-30
RECRUITING
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeNCT07341867 · 2026-07-30
RECRUITING
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid MalignanciesNCT07613723 · 2026-05-11
RECRUITING
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerNCT07441460 · 2026-03-06
RECRUITING
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid TumorsNCT07523529 · 2026-03-02
RECRUITING
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate CancerNCT07641049 · 2026-03-02
RECRUITING
Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal MesotheliomaNCT07510815 · 2026-03-02
RECRUITING
A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBCNCT07178171 · 2025-11-06
RECRUITING
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsNCT04119024 · 2025-10-07
RECRUITING
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBCNCT07016399 · 2025-09-09
RECRUITING
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNCT06885697 · 2025-07-08
RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30
RECRUITING
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast CancerNCT06802757 · 2025-05-01
RECRUITING
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)NCT06797635 · 2025-03-20
RECRUITING
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast CancerNCT06291064 · 2025-03-18
RECRUITING
Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin ReactionsNCT07362914 · 2025-03-07
RECRUITING
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast CancerNCT05989828 · 2024-12-17
RECRUITING
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerNCT06236139 · 2024-11-26
RECRUITING
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPCNCT06193486 · 2024-10-26
RECRUITING
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY TrialNCT06042569 · 2024-09-16
RECRUITING
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung CancerNCT06538012 · 2024-08-20
RECRUITING
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T CellsNCT06347068 · 2024-06-27
RECRUITING
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast CancerNCT06318897 · 2024-05-29
RECRUITING
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBCNCT06245889 · 2024-05-01
RECRUITING
Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast CancerNCT07635342 · 2024-04-30
RECRUITING
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast CancerNCT06389006 · 2024-04-29
RECRUITING
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.NCT06072612 · 2023-12-05
RECRUITING
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerNCT06058377 · 2023-11-27
RECRUITING
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast CancerNCT06085742 · 2023-11-22
RECRUITING
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerNCT06121557 · 2023-11-01
RECRUITING
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerNCT06121570 · 2023-11-01
RECRUITING
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast CancerNCT05900206 · 2023-10-26
RECRUITING
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant ChemotherapyNCT05978648 · 2023-09-20
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerNCT05929768 · 2023-09-15
RECRUITING
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerNCT05981001 · 2023-08-01
RECRUITING
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerNCT05981014 · 2023-08-01
RECRUITING
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast CancerNCT05883852 · 2023-06-07
RECRUITING
TCb vs EC-T in High Risk ER+/HER2- Breast CancerNCT05901428 · 2023-06-01
RECRUITING
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast CancerNCT05020860 · 2023-04-18
RECRUITING

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.